Triple-positive breast carcinoma
MONDO:0700078A breast carcinoma which is positive for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
Also known as: HR-positive HER2 positive breast cancer, hormone receptor positive her2 positive breast cancer, triple positive breast cancer
2827 clinical trials for this condition and its sub-types, 33 tagged with Triple-positive breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Chemo-Free hope: pill combo aims to shrink HER2+ breast tumors
Disease control CompletedThis phase II trial is testing whether a combination of palbociclib (a targeted pill), hormone therapy, and HER2-targeted drugs can shrink early-stage breast tumors as effectively as standard chemotherapy before surgery. Postmenopausal women with hormone receptor-positive, HER2-p…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Triple attack on tough breast cancer: combining targeted therapies may improve outcomes
Disease control CompletedThis trial is for women with advanced breast cancer that has both hormone receptors (HR-positive) and the HER2 protein (HER2-positive). It tests whether adding a CDK4/6 inhibitor called palbociclib to standard endocrine therapy and anti-HER2 antibodies (trastuzumab and pertuzumab…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new drug combination (fluzoparib plus chemotherapy) given before surgery to 28 women with a specific type of early breast cancer (HR+/HER2- with HRD). The goal was to see if it could shrink tumors more effectively. The treatment was given over 8 cycles, and th…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC